Popular Articles

Changes In Brain Architecture May Be Driven By Different Cognitive Challenges
Scientists trying to understand how the brains of animals evolve have found that evolutionary changes in brain structure reflect the types of social interactions and environmental stimuli different species face.
generic viagra online
ARCA Biopharma Receives Complete Response Letter From FDA On The GencaroTM NDA
ARCA biopharma, Inc. (Nasdaq:ABIO) announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA, or the Agency) for its New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure.
News of the day
Vyvanse CII Significantly Improved ADHD Symptoms For Children 13 Hours After Administration
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.
Mental Health

Shire Selects SAS(R) Drug Development To Handle Clinical Trials Data

SAS, the leader in business analytics, announced that Shire, the global specialty biopharmaceutical company, has selected SAS® Drug Development as the platform for its clinical trials data. "Shire is excited about our partnership with SAS, and we look forward to leveraging the SAS Drug Development platform to manage our clinical trial data," said Nick Ronca, Associate Director Clinical R&D, Shire Pharmaceuticals. SAS Drug Development is available as a standalone or hosted solution with access via a secure, thin client. A centralized repository allows life sciences firms to aggregate, analyze and review clinical trials data to determine safety and efficacy outcomes. "Our approach at SAS allows our customers, like Shire, to be more focused and efficient in developing and delivering medicines to patients and their families around the world," said Jason Burke, Global Director of Health and Life Sciences for SAS. 21 CFR and CDISC Compliant SAS Drug Development allows rapid and reliable validation and implementation, eliminating strain on limited IT infrastructure and res. The solution is compliant with global agency regulations, such as 21 CFR Part 11, which is often difficult to attain. "Our hosted global environment contains a single view of the targeted clinical data in a secured and qualified environment so scientists, programmers and statisticians can view the most up-to-date, accurate information" said Burke. SAS" scalability and flexibility were features important to Shire, which has grown rapidly through acquisitions and mergers over its nearly twenty-five year history. Shire, which has a presence in 23 countries and markets medicines in more than 45 countries, needed a global solution for managing and processing its clinical trial data. "Working in unison with SAS allows Shire to focus on meeting its mission, and investing in its product portfolio instead of developing a complex IT infrastructure to support clinical data," said Burke. SAS Implementation Team Relying on the SAS Consulting Group that has successfully deployed SAS Drug Development in the past, Shire believes that the system will maximize the best practices of both Shire and SAS. SAS is demonstrating SAS Drug Development at the DIA 45th Annual Meeting in Booth 301. SAS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):